Clinical and hematologic features of patients with CMML included in the study
| Variable . | Learning cohort . | Validation cohort . |
|---|---|---|
| Patients, n | 214 | 260 |
| Follow-up in months, median (range) | 22 (0.4-212.6) | 17 (0.2-155) |
| Age in years, median (range) | 72 (28-99) | 74 (22-93) |
| Males, n (%) | 151 (71) | 190 (73) |
| FAB subtype, n (%) | ||
| CMML-MD | 129 (60) | 148 (57) |
| CMML-MP | 85 (40) | 112 (43) |
| WHO subtype, n (%) | ||
| CMML-0 | 138 (64) | 112 (44) |
| CMML-1 | 38 (18) | 74 (28) |
| CMML-2 | 38 (18) | 74 (28) |
| WBC count, × 109/L, median (range) | 9.8 (1.2-126) | 11.0 (2.0-87.0) |
| Absolute monocyte count, × 109/L, median (range) | 2.06 (0.97-34.01) | 3.37 (1.02-39.95) |
| Hemoglobin level (g/dL), median (range) | 11.6 (6-16.6) | 11.5 (5.9-17) |
| Platelet count (× 109/L), median (range) | 124 (4-943) | 103 (3-1385) |
| BM blasts* (%), median (range) | 3 (1-18) | 6 (0-19) |
| Chromosomal abnormalities, n (%) | 44 (23) | 58 (22) |
| Median survival (mo) | 48.4 | 51.2 |
| CPSS cytogenetic risk group,†n (%) | ||
| Low | 150 (79) | 218 (84) |
| Intermediate | 21(11) | 13 (5) |
| High | 19 (10) | 29 (11) |
| CPSS risk group,‡n (%) | ||
| Low | 85 (46) | 84 (32) |
| Intermediate-1 | 49 (27) | 102 (39) |
| Intermediate-2 | 46 (25) | 66 (25) |
| High | 4 (2) | 8 (3) |
| Variable . | Learning cohort . | Validation cohort . |
|---|---|---|
| Patients, n | 214 | 260 |
| Follow-up in months, median (range) | 22 (0.4-212.6) | 17 (0.2-155) |
| Age in years, median (range) | 72 (28-99) | 74 (22-93) |
| Males, n (%) | 151 (71) | 190 (73) |
| FAB subtype, n (%) | ||
| CMML-MD | 129 (60) | 148 (57) |
| CMML-MP | 85 (40) | 112 (43) |
| WHO subtype, n (%) | ||
| CMML-0 | 138 (64) | 112 (44) |
| CMML-1 | 38 (18) | 74 (28) |
| CMML-2 | 38 (18) | 74 (28) |
| WBC count, × 109/L, median (range) | 9.8 (1.2-126) | 11.0 (2.0-87.0) |
| Absolute monocyte count, × 109/L, median (range) | 2.06 (0.97-34.01) | 3.37 (1.02-39.95) |
| Hemoglobin level (g/dL), median (range) | 11.6 (6-16.6) | 11.5 (5.9-17) |
| Platelet count (× 109/L), median (range) | 124 (4-943) | 103 (3-1385) |
| BM blasts* (%), median (range) | 3 (1-18) | 6 (0-19) |
| Chromosomal abnormalities, n (%) | 44 (23) | 58 (22) |
| Median survival (mo) | 48.4 | 51.2 |
| CPSS cytogenetic risk group,†n (%) | ||
| Low | 150 (79) | 218 (84) |
| Intermediate | 21(11) | 13 (5) |
| High | 19 (10) | 29 (11) |
| CPSS risk group,‡n (%) | ||
| Low | 85 (46) | 84 (32) |
| Intermediate-1 | 49 (27) | 102 (39) |
| Intermediate-2 | 46 (25) | 66 (25) |
| High | 4 (2) | 8 (3) |